mohd izzuan
Aurinia Pharmaceuticals (NASDAQ:AUPH) stock jumped 14% in afternoon trading Thursday after the company reported better-than-expected Q3 revenue and announced it was cutting around 45% of its workforce to focus on the commercialization of its lupus drug Lupkynis.
For the third
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。